Fulvestrant (ICI-182780) Mechanism of Action: ER Inhibition in Breast Cancer Cell Research

Fulvestrant (ICI-182780) MOA：Targeting ER/PI3K-AKT-mTOR Pathway for Targeted Therapy Combinations

🎯 check Fulvestrant (ICI-182780) product page

Fulvestrant is a potent ER antagonist. It affects ER signaling pathways, by degrading ER, thereby inhibiting tumor growth.

Primary Applications and Mechanism of Action

Jump to: